<DOC>
	<DOCNO>NCT01846416</DOCNO>
	<brief_summary>This multicenter , single-arm study evaluate efficacy safety atezolizumab ( MPDL3280A ) participants PD-L1-positive locally advanced metastatic NSCLC . Participants receive intravenous ( IV ) dose 1200 milligram ( mg ) atezolizumab ( MPDL3280A ) Day 1 21-day cycle disease progression . Eligible participant categorize three group follow : 1 . Participants prior chemotherapy advance disease ; 2 . Participants progress follow prior-platinum base chemotherapy regimen advance disease ( 2L+participants ) ; 3 . Participants 2L+ previously treat brain metastasis .</brief_summary>
	<brief_title>A Study Atezolizumab Participants With Programmed Death-Ligand 1 ( PD-L1 ) Positive Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC ) FIR</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Stage IIIB ( eligible definitive chemoradiotherapy ) , Stage IV , recurrent NSCLC PDL1positive status determine immunohistochemistry assay performed central laboratory . A positive result chemotherapy , chemoradiation tumor sample biopsy satisfy eligibility criterion Eastern Cooperative Oncology group Performance Status 0 1 Life expectancy great equal 12 week Measurable disease , define Response Evaluation Criteria Solid Tumors Version 1.1 Adequate hematologic end organ function Any approve anticancer therapy , include chemotherapy , hormonal therapy within 3 week prior initiation study treatment ; follow exception allow . Hormonereplacement therapy oral contraceptive , tyrosine kinase inhibitor approve treatment NSCLC discontinue great 7 day prior Cycle 1 Day 1 Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment Known central nervous system disease , include treat brain metastasis follow participant : 1. receive prior chemotherapy advance disease 2. progress follow priorplatinum base chemotherapy regimen advance disease ( refer 2L+ participant ) Participants history treat asymptomatic brain metastasis allow 2L+ participant previously treat brain metastasis . Leptomeningeal disease Uncontrolled tumorrelated pain Uncontrolled hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>